Combination nivolumab and ipilimumab or nivolumab alone in melanoma brain metastases: a multicentre randomised phase 2 study-Reference-Cited by-同舟云学术

Combination nivolumab and ipilimumab or nivolumab alone in melanoma brain metastases: a multicentre randomised phase 2 study

Published:2018-05 Issue:5 Volume:19 Page:672-681
ISSN:1470-2045
Container-title:The Lancet Oncology
language:en
Short-container-title:The Lancet Oncology

Author:

Long Georgina V,Atkinson Victoria,Lo Serigne,Sandhu Shahneen,Guminski Alexander D,Brown Michael P,Wilmott James S,Edwards Jarem,Gonzalez Maria,Scolyer Richard A,Menzies Alexander M,McArthur Grant A

Publisher

Elsevier BV

Subject

Oncology

Reference17 articles.

1. Prognostic Factors for survival in melanoma patients with brain metastases;Davies;Cancer,2011

2. Determinants of outcome in melanoma patients with cerebral metastases;Fife;J Clin Oncol,2004

3. Overall survival with combined nivolumab and ipilimumab in advanced melanoma;Wolchok;N Engl J Med,2017

4. Cobimetinib combined with vemurafenib in advanced BRAFV600-mutant melanoma (coBRIM): updated efficacy results from a randomised, double-blind, phase 3 trial;Ascierto;Lancet Oncol,2016

5. Dabrafenib and trametinib versus dabrafenib and placebo for Val600 BRAF-mutant melanoma: a multicentre, double-blind, phase 3 randomised controlled trial;Long;Lancet,2015

Cited by 791 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Melanoma Brain Metastasis;Hematology/Oncology Clinics of North America;2024-10

2. Treatment of melanoma brain metastases with radiation and immunotherapy or targeted therapy: A systematic review with meta-analysis;Critical Reviews in Oncology/Hematology;2024-10

3. Targeting PD-1/PD-L1 in tumor immunotherapy: Mechanisms and interactions with host growth regulatory pathways;Cytokine & Growth Factor Reviews;2024-10

4. “Symptomatic” melanoma brain metastases: A call for clear definitions and adoption of standardized tools;European Journal of Cancer;2024-09

5. Brain-Metastatic Melanoma Models Uncover Immune and Molecular Correlates of Response to Immunotherapy;2024-08-28